Support Alert

Drug safety update: Loperamide (Imodium): reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update following reports of cardiac events including QT prolongation, torsades de pointes, and cardiac arrest in patients who have taken high or very high doses of loperamide as a drug of abuse or for self-treatment of opioid withdrawal.

Further details of the safety update, advice and action to take are available on the MHRA website.